Press Review from 20/06/08 to the 23/06/08
"Inquiry into drugs, AIFA leaders suspended"
(Il Sole 24 Ore: page 14, Il Messaggero: page 12, Corriere della Sera: page 19, Libero: page 16, la Repubblica: page 17, Il Mattino: page 12 – 22 June 2008)
The General Manager of AIFA Nello Martini was suspended, as a precaution for 2 months, from his functions and with him also Caterina Gualano, manager for marketing authorizations. The accusation is of 'culpable disaster with conscious negligence', inherent in the investigation into the delayed updating of the leaflets of some drugs. Martini will ask for an international expert opinion and will present an appeal to the Lazio Regional Administrative Court, where the investigation has been transferred.
http://www.aboutpharma.it/notizia.asp?id=17020
"Newron auctions ralfinamide jewel"
(Stock Exchange & Finance: page 9 – 21 June 2008)
Newron Pharmaceuticals may sell rights to experimental painkiller ralfinamide. This measure would give a boost to the biotech company's shares which have recorded a decrease of 36.8% since the beginning of 2008. Newron is also evaluating the hypothesis of external growth: CEO Luca Benatti believes that 'with an acquisition you enter the market faster. The ideal target would be a company similar to Newron'.
http://www.aboutpharma.it/notizia.asp?id=17021
